Lam Allan Hoi Kin, Co Michael Tiong Hong, Kwong Ava
Division of Breast Surgery, Department of Surgery, The University of Hong Kong, Hong Kong, China.
J Clin Med. 2024 Jan 23;13(3):643. doi: 10.3390/jcm13030643.
Breast cancer is the most common cancer among women globally and can be classified according to various histological subtypes. Current treatment strategies are typically based on the cancer stage and molecular subtypes. This article aims to address the knowledge gap in the understanding of rare breast cancer. A retrospective study was conducted on 4393 breast cancer patients diagnosed from 1992 to 2012, focusing on five rare subtypes: mucinous, invasive lobular, papillary, mixed invasive and lobular, and pure tubular/cribriform carcinomas. Our analysis, supplemented by a literature review, compared patient characteristics, disease characteristics, and survival outcomes of rare breast cancer patients with invasive carcinoma (not otherwise specified (NOS)). Comparative analysis revealed no significant difference in overall survival rates between these rare cancers and the more common invasive carcinoma (NOS). However, mucinous, papillary, and tubular/cribriform carcinomas demonstrated better disease-specific survival. These subtypes presented with similar characteristics such as early detection, less nodal involvement, more hormonal receptor positivity, and less human epidermal growth factor receptor 2 (HER2) positivity. To conclude, our study demonstrated the diversity in the characteristics and prognosis of rare breast cancer histotypes. Future research should be carried out to investigate histotype-specific management and targeted therapies, given their distinct behavior.
乳腺癌是全球女性中最常见的癌症,可根据多种组织学亚型进行分类。当前的治疗策略通常基于癌症分期和分子亚型。本文旨在填补对罕见乳腺癌认识方面的知识空白。对1992年至2012年诊断的4393例乳腺癌患者进行了一项回顾性研究,重点关注五种罕见亚型:黏液性癌、浸润性小叶癌、乳头状癌、浸润性和小叶混合性癌以及纯管状/筛状癌。我们的分析辅以文献综述,比较了罕见乳腺癌患者与浸润性癌(未另行指定(NOS))患者的特征、疾病特征和生存结果。比较分析显示,这些罕见癌症与更常见的浸润性癌(NOS)的总生存率无显著差异。然而,黏液性癌、乳头状癌和管状/筛状癌表现出更好的疾病特异性生存率。这些亚型具有相似的特征,如早期发现、较少的淋巴结受累、更多的激素受体阳性以及较少的人表皮生长因子受体2(HER2)阳性。总之,我们的研究证明了罕见乳腺癌组织学类型在特征和预后方面的多样性。鉴于其独特的行为,未来应开展研究以调查组织学类型特异性管理和靶向治疗。